DexCom, Inc. (DXCM)
| Market Cap | 24.77B |
| Revenue (ttm) | 4.52B |
| Net Income (ttm) | 720.70M |
| Shares Out | 390.02M |
| EPS (ttm) | 1.80 |
| PE Ratio | 35.35 |
| Forward PE | 26.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,209,009 |
| Open | 62.79 |
| Previous Close | 63.47 |
| Day's Range | 62.32 - 63.98 |
| 52-Week Range | 54.11 - 93.25 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 87.24 (+37.34%) |
| Earnings Date | Oct 30, 2025 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time... [Read more]
Financial Performance
In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $87.24, which is an increase of 37.34% from the latest price.
News
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review
The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were...
Touchstone Sands Capital Select Growth Fund Q3 Contributors And Detractors
Positioning within the Magnificent 7 was the primary driver of poor security selection and relative underperformance. The Fund's holdings in businesses viewed as key enablers of AI were strong contrib...
Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stoc...
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
Del Mar, California--(Newsfile Corp. - November 25, 2025) - American Diversified Holdings Corporation (OTCID: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DE...
Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc.
MILWAUKEE , Nov. 24, 2025 /PRNewswire/ -- Ademi & Fruchter LLP is investigating possible securities fraud claims against DexCom, Inc. (NASDAQ: DXCM). The investigation results from inaccurate statemen...
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting starte...
Top 2 Healthcare Stocks Every New Investor Should Know
These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age...
Dexcom partners with Disabled American Veterans as part of new strategic initiative
ERLANGER, Ky., Nov. 19, 2025 (GLOBE NEWSWIRE) -- In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global lea...
Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insuli...
DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT Investors With Large Losses in DexCom, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of ...
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be limit...
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
DexCom was hit with a recall and several lawsuits after some customers complained about its devices. Despite this current challenge, the medical device leader is delivering solid financial results.
Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately
Lead Plaintiff Deadline is December 26, 2025 NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has be...
DXCM STOCK NOTICE: DexCom, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 26 Deadline
New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXC...
Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
MONTREAL--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Mo...
Is Dexcom Stock A Buy Now?
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past...
S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops
Shares of an e-commerce and cloud computing powerhouse delivered big gains on the final day of October, while a medical device maker came under pressure after an executive provided an underwhelming ou...
Why DexCom Stock Is Crashing Today
DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins.
DexCom Stock Is the Worst Performer in the S&P 500. Here's Why.
The maker of diabetes technology posts better-than-expected revenue but shares are falling.
20% Earnings Growth Potential For DexCom, Analyst Cites Buying Opportunity
DexCom, Inc.'s (NASDAQ:DXCM) third-quarter 2025 revenue reached $1.209 billion, beating the analyst consensus estimate of $1.179 billion.
Dexcom shares extend fall over 2026 growth concerns
Dexcom shares tumbled 12% in premarket trading on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.